Genetic testing of breast and ovarian cancer patients: Clinical characteristics and hormonal risk modifiers

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 85, Issue 1, 1999, Pages 75-80

  Kaduri, Luna ^a   Gibs, Maya ^a   Hubert, Ayala ^a   Sagi, Michal ^a   Heching, Norman ^a   Lerer, Israela ^a   Uziely, Bietrice ^a   Weinberg, Naomi ^a   Abeliovich, Dvorah ^a   Peretz, Tamar ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Ashkenazi founder mutations; BRCA1 2; Breast cancer; Hormonal effects; Ovarian cancer; Prevention

Indexed keywords

AGE DISTRIBUTION; BREAST CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DECISION MAKING; FEMALE; FERTILIZATION; GENE MUTATION; GENETIC ANALYSIS; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MENARCHE; MENOPAUSE; OVARY CANCER; PRACTICE GUIDELINE; PREGNANCY RATE; PRIMIGRAVIDA; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0033039129     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(98)00286-3     Document Type: Conference Paper

References (21)

1. Simard J., Tonin P., Durocher F., Morgan K., Rommens J., Gingras S., Samson C.et al. Common origin of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet. 8:1994;392-398.
2. Berman D.B., Wagner-Costalas J., Schultz D.C., Lynch H.T., Daly M., Godwin A.K. Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG mutation kindreds. Am J Hum Genet. 58:1996;1166-1176.
3. Neuhausen S.L., Gilewski T., Norton L., Tram T., McGuire P., Swensen J., Hampel H.et al. Recurrent BRCA2 6174delT mutation in Ashkenazi Jewish women affected by breast cancer. Nat Genet. 13:1996;126-128.
4. Fodor F.H., Weston A., Bleiweiss I.J., McCurdy L.D.et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet. 63:1998;45-51.
5. Claus E.B., Schildkraut J.M., Thompson W.P., Risch N.J. The genetic attributable risk of breast and ovarian cancer. Cancer. 77:1996;2318-2324.
6. Miki Y., Swensen J., Shuttuck E.D.et al. A strong candidate for the breast and ovarian susceptibility gene BRCA1. Science. 266:1994;66-71.
7. Struewing J.P., Hartge P., Wacholder S.et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New Engl J Med. 336:1997;1401-1408.
8. Whittemore A.S., Gong G., Itngre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three US population-based case-control studies of ovarian cancer. Am J Hum Genet. 60:1997;496-504.
9. Narod S.A., Goldgar D., Canon-Albright L., Weber B., Moslehi R., Ives E., Lenoir G., Lynch H. Risk modifiers in carriers of BRCA1 mutations. Int J Can. 64:1995;394-398.
10. Ursin G., Henderson B.E., Haile R.W., Pike M.C., Zhou N., Diep A., Bernstein L. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women. Cancer Res. 57:1997;3678-3681.
11. Fletcer S.W., Black W., Harris R., Rimer B.K., Shapiro S. Report of the international workshop on screening for breast cancer. J Natl Cancer Inst. 85(20):1993;1644-1656.
12. Jacobs I., Bridges J., Reynolds C.et al. Multimodal approach to screening for ovarian cancer. Lancet. 2:1988;268-271.
13. Einhorn N., Sjovall K., Schoenfeld D.A.et al. Prospective evaluation of the specificity of serum CA125 levels for detection of ovarian cancer in normal population. Am Soc Clin Oncol. 9:1990;157.
14. Abeliovich D., Kaduri L., Lerer I., Weinberg N.et al. The founder mutations 185delAG and 5382insc in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early onset breast cancer patients among Ashkenazi woman. Am J Hum Genet. 60:1997;505-514.
15. Friedman E., Bar-Sade Bruchim R., Kruglikova A. Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. Am J Hum Genet. 63:1998;1224-1227.
16. Schrag D., Kunts K.M., Garber J.E., Weeks J.C. Decision analysis-effect of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. New Engl J Med. 336:1997;1465-1471.
17. Grann V.R., Panageas K.S., Whang W., Antman K.H., Neugut A.I. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1 positive or BRCA2 positive patients. J Clin Oncol. 16:1998;979-985.
18. Eisinger F., Renoire J.C., Chabal F., Loquet C., Moatti J., Sobol H. Acceptable strategies for dealing with hereditary breast/ovarian cancer risk. J Natl Cancer Inst. 89:1997;731.
19. Robson M., Levine D., Brown B.et al. Results of breast conservation therapy for invasive breast cancer in women with BRCA mutations. Proc Am Soc Clin Oncol. 17:1998;2103.
20. Henderson B.E., Ross R.K., Pike M.C. Hormonal chemoprevention in women. Science. 259:1993;633-638.
21. Gudas J.M., Ngugen H., Li T., Cowan K.H. Hormone dependant regulation of BRCA1 in human breast cancer cells. Cancer Res. 55:1995;4561-4565.